Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
3 Buy-Rated Stocks Displaying Notable Price Strength
05:00pm, Wednesday, 16'th Aug 2023
Many stocks have displayed relative strength in the recent term, providing investors with sizable gains.
Wegovy could prevent up to 1.5 million heart attacks, strokes over 10 years, study says
04:38pm, Wednesday, 16'th Aug 2023
The results complement the data Novo Nordisk released last week, which found Wegovy slashed the risk of serious heart problems and heart-related death by 20%.
Prediction: These 2 Stocks Could Double by 2030
09:45am, Wednesday, 16'th Aug 2023
Growing revenue, an improving bottom line, and exciting opportunities paint a bright future for Exact Sciences. Novo Nordisk is virtually unmatched in the diabetes drug market, with more potential med
Novo Nordisk (NVO) Rides on Ozempic & Wegovy Amid Rivalry
10:55am, Tuesday, 15'th Aug 2023
Novo Nordisk (NVO) continues to witness increasing demand for its diabetes and obesity care products like Ozempic, Wegovy and Rybelsus amid rising competition from other pharma bigwigs.
2 Stocks That Raised EPS but Lowered Revenue Estimates
08:27am, Monday, 14'th Aug 2023
Growth or value? Top or bottom line?
Why Novo Nordisk Stock Soared 16% This Week
06:37am, Saturday, 12'th Aug 2023
Novo Nordisk rose on news of encouraging outcomes for its SELECT trial of weight loss drug semaglutide. The Danish pharmaceutical leader also raised its full-year sales and profit outlook after postin
3 Reasons Why Novo Nordisk (NVO) Is a Great Growth Stock
01:47pm, Friday, 11'th Aug 2023
Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Novo Nordisk raises full-year outlook as Wegovy sales skyrocketed in 2Q
03:49pm, Thursday, 10'th Aug 2023
Novo Nordisk (NYSE:NVO) has raised its full-year outlook based on a strong first half of 2023 driven by continued high demand for its popular weight-loss drug Wegovy. The Denmark-headquartered globa
Novo Nordisk Boosts Guidance as Sales of Weight-Loss Drug Wegovy Soar
01:46pm, Thursday, 10'th Aug 2023
Novo Nordisk raised its outlook as revenue from its popular weight-loss treatment, Wegovy, skyrocketed.
Novo Nordisk reports earnings miss, sees profit and sales growth
12:18pm, Thursday, 10'th Aug 2023
Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down Novo Nordisk's Q2 earnings which included profit up 43% and sales up 30%.
Novo Nordisk (NVO) Q2 Earnings and Sales Miss, 2023 View Up
12:15pm, Thursday, 10'th Aug 2023
Novo Nordisk (NVO) reports weaker-than-expected second-quarter 2023 results, missing both earnings and sales estimates. Management, however, raises 2023 guidance.
Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion
11:56am, Thursday, 10'th Aug 2023
Inversago's drugs use a different approach than most treatments in the obesity and diabetes space.
Novo eyes other health benefits from weight-loss drug Wegovy after major trial
08:36am, Thursday, 10'th Aug 2023
Novo Nordisk hopes to show additional health benefits from taking its hugely popular drug Wegovy, apart from losing weight and cutting the risk of heart disease, its drug development executive told Re
Novo Nordisk: weight-loss Wegovy drug's heart benefits will help discussions with payers
08:10am, Thursday, 10'th Aug 2023
Novo Nordisk expects new data showing the heart benefits of its weight-loss drug Wegovy will help its discussions with public health authorities and other payers about the benefits of paying for it, e
Novo Nordisk's limits on Wegovy US supply seen into 2024, CEO says
05:38am, Thursday, 10'th Aug 2023
Novo Nordisk's limits on U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug will likely last into next year, CEO Lars Fruergaard Jorgensen told Reuters on Thursday.
